Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin-based therapeutics ...
Currently, the Company is exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. Revive is also advancing the development of Psilocybin-based ...
TORONTO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive ... evaluating Bucillamine as a potential treatment for nerve agent exposure, in partnership with Defence R ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback